Chemical composition of juice and antihyperglycemic studies in seed of the prehispanic fruit tunillo (Stenocereus stellatus) collected in Oaxaca, Mexico

580-584Tunillo, or pitaya of august (Stenocereus stellatus) is a prehispanic fruit, endemic to the Mixteca region in Mexico and to which a lot of medicinal properties have been associated. However, there are few scientific studies regarding its characterization and use. For these reasons, in this study we carried out a chemical characterization of the juice of four-color variants as well as determine the antihyperglycemic capacity of seed. Physical and chemical characterization were carried out in juice of fruits of Stenocereus after a preselection based on pulp color. Total soluble solids, pH, titratable acidity, organic acid and betalains were quantified in juice and antihyperglycemic capacity was measured in seed. Physicochemical parameters in juice were similar in the 4 variants; regarding the content of pigments, the red variant showed the highest values as well as the highest organic acids. However, the white, orange, and red variants showed better antihyperglycemic capacity. Red tunillo is the best candidate for obtaining pigments and its higher organic acids content correlates with its lower acceptance by the local population. The seeds of the white, orange, and red colors showed promising anhyperglycemic capacity, which suggest that they should be considered for the development of antidiabetic treatments. These results contribute to the use of compex matrices considered waste products of the fruits. This would undoubtedly increase their commercial value

Chemical composition of juice and antihyperglycemic studies in seed of the prehispanic fruit tunillo (Stenocereus stellatus) collected in Oaxaca, Mexico

Tunillo, or pitaya of august (Stenocereus stellatus) is a prehispanic fruit, endemic to the Mixteca region in Mexico and to which a lot of medicinal properties have been associated. However, there are few scientific studies regarding its characterization and use. For these reasons, in this study we carried out a chemical characterization of the juice of four-color variants as well as determine the antihyperglycemic capacity of seed. Physical and chemical characterization were carried out in juice of fruits of Stenocereus after a preselection based on pulp color. Total soluble solids, pH, titratable acidity, organic acid and betalains were quantified in juice and antihyperglycemic capacity was measured in seed. Physicochemical parameters in juice were similar in the 4 variants; regarding the content of pigments, the red variant showed the highest values as well as the highest organic acids. However, the white, orange, and red variants showed better antihyperglycemic capacity. Red tunillo is the best candidate for obtaining pigments and its higher organic acids content correlates with its lower acceptance by the local population. The seeds of the white, orange, and red colors showed promising anhyperglycemic capacity, which suggest that they should be considered for the development of antidiabetic treatments. These results contribute to the use of compex matrices considered waste products of the fruits. This would undoubtedly increase their commercial value

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

4to. Congreso Internacional de Ciencia, Tecnología e Innovación para la Sociedad. Memoria académica

Este volumen acoge la memoria académica de la Cuarta edición del Congreso Internacional de Ciencia, Tecnología e Innovación para la Sociedad, CITIS 2017, desarrollado entre el 29 de noviembre y el 1 de diciembre de 2017 y organizado por la Universidad Politécnica Salesiana (UPS) en su sede de Guayaquil. El Congreso ofreció un espacio para la presentación, difusión e intercambio de importantes investigaciones nacionales e internacionales ante la comunidad universitaria que se dio cita en el encuentro. El uso de herramientas tecnológicas para la gestión de los trabajos de investigación como la plataforma Open Conference Systems y la web de presentación del Congreso http://citis.blog.ups.edu.ec/, hicieron de CITIS 2017 un verdadero referente entre los congresos que se desarrollaron en el país. La preocupación de nuestra Universidad, de presentar espacios que ayuden a generar nuevos y mejores cambios en la dimensión humana y social de nuestro entorno, hace que se persiga en cada edición del evento la presentación de trabajos con calidad creciente en cuanto a su producción científica. Quienes estuvimos al frente de la organización, dejamos plasmado en estas memorias académicas el intenso y prolífico trabajo de los días de realización del Congreso Internacional de Ciencia, Tecnología e Innovación para la Sociedad al alcance de todos y todas

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Effect of supplementary irrigation on the transpiration and reproductive development of oil palm trees during the dry season in Tabasco, Mexico

Some oil palm production zones have periods of low rainfall, eliciting to water stress and impacting yields. The objective of this study was to evaluate the effect of the supplementary irrigation application during the dry season, on the water use and the transpiration of oil palm trees, and on morphological changes that occur during the different phenological stages. The monitored site was an oil palm plantation in Jalapa, Tabasco, Mexico (17° 38 N; 92° 56 W; altitude 20 m). There, the plant density is 143 palms ha−1. Two areas of palm trees with ages of 6 and 11 years were located. The soil type was classified as Gleysol. A weather station was placed in a pasture adjacent (1 km) to the plantation. The variables, evaluated from April 1 to June 23, 2017, included the structural characteristics of the plantation, sap flow, transpiration, and the morphological changes at the different phenological stages, which were assessed based on the BBCH scale. The results showed that the water use per palm tree (102–140 kg day−1) and the transpiration (1.59–2.11 mm day−1) were not significantly different among palm trees ages. The application of irrigation during the dry season maintained transpiration in palms of both ages and favoured inflorescence development and fruit formation by shortening the number of days it took the palm plants to reach fruit formation stage (stages 503-700), but increased the number of days required by the bunches to reach maturation (stages 709 to harvest). This study conducted during few months needs to be confirmed by longer term monitoring

Vivero Centroamericano de adaptación y rendimiento: VICAR 1983-1984

Centro Internacional de Agricultura Tropical (CIAT)UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Agroalimentarias::Estación Experimental Agrícola Fabio Baudrit Moreno (EEAFBM